📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Amanta Healthcare Promoter Bhavesh Patel Acquires 28,800 Shares via Open Market
Shri Bhavesh Patel, the Promoter, Chairman, and Managing Director of Amanta Healthcare, has purchased 28,800 equity shares of the company. These transactions were conducted through the open market on March 27 and March 30, 2026. The disclosure was made in compliance with SEBI (Prohibition of Insider Trading) Regulations. Such insider buying by the top-most executive is generally perceived as a strong signal of confidence in the company's future performance and valuation.
Key Highlights
Promoter and CMD Shri Bhavesh Patel acquired 28,800 equity shares from the open market.
The acquisition took place across two trading sessions on March 27 and March 30, 2026.
Disclosure filed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
The purchase reflects management's direct financial commitment to the company's growth trajectory.
💼 Action for Investors
Investors should take this as a positive cue regarding the company's internal outlook. It is advisable to monitor if the promoter continues to increase their stake in subsequent quarters.
Loading analysis...
Amanta Healthcare Promoter Bhavesh Patel Acquires 48,151 Shares via Open Market
Shri Bhavesh Patel, a promoter of Amanta Healthcare Limited, has increased his stake by purchasing 48,151 equity shares from the open market. The acquisition took place over two trading sessions on February 26 and February 27, 2026. This transaction was disclosed under the SEBI (Prohibition of Insider Trading) Regulations, 2015. Such insider buying typically signals strong promoter confidence in the company's future prospects and intrinsic value.
Key Highlights
Promoter Shri Bhavesh Patel purchased a total of 48,151 equity shares.
The acquisition was conducted through open market transactions on February 26 and 27, 2026.
The disclosure was filed in compliance with Regulation 7(2) of SEBI Insider Trading rules.
The move indicates increased 'skin in the game' by the promoter group.
💼 Action for Investors
Investors should view this promoter buying as a positive sign of internal confidence, though it should be weighed against the company's overall financial performance.
Loading analysis...
CRISIL Upgrades Amanta Healthcare’s Long-Term Rating to 'BBB/Stable' on Improved Financial Profile
CRISIL has upgraded Amanta Healthcare's long-term rating to 'BBB/Stable' and short-term rating to 'A3+', reflecting a significantly strengthened financial position. The upgrade follows a successful IPO that raised Rs 126 crore, boosting net worth to Rs 211 crore as of September 2025 and reducing gearing from 2.02 to 0.84. The company maintains healthy operating margins of 21-22% and is expanding capacity for its Steriport and SVP brands, expected to go live in April 2026. This improved credit profile suggests lower borrowing costs and better financial stability for future growth.
Key Highlights
Long-term credit rating upgraded to 'CRISIL BBB/Stable' from 'CRISIL BBB-/Stable' for Rs 245 crore bank facilities.
Net worth increased to Rs 211 crore from Rs 96 crore following a Rs 126 crore IPO infusion.
Debt-to-equity (gearing) ratio improved significantly to 0.84x from 2.02x as of September 2025.
Operating margins remain healthy at approximately 22% for the first half of fiscal 2026.
Capacity expansion for Steriport and SVP brands is scheduled for completion by April 2026 to drive future revenue.
💼 Action for Investors
Investors should view this upgrade as a sign of reduced financial risk and improved balance sheet strength following the IPO. Monitor the timely commencement of the new capacity in April 2026 as it is the primary catalyst for medium-term growth.
Loading analysis...
Amanta Healthcare Q3 PAT Rises 8.1%; Targets ₹150 Cr Incremental Revenue from Expansion
Amanta Healthcare reported a steady Q3 FY26 with revenue growing 9.8% YoY to ₹75 crores and PAT increasing 8.1% to ₹5 crores. The company is nearing a major growth phase, doubling its SteriPort capacity to 12 crore bottles per annum with commercialization expected in April 2026. Management anticipates an incremental revenue potential of ₹150 crores from the combined LVP and SVP expansions. Additionally, a 10.8 MW captive solar plant is expected to save ₹9 crores annually starting Q1 FY27, which will significantly enhance operating leverage.
Key Highlights
Q3 FY26 revenue grew 9.8% YoY to ₹75 crores, while 9M PAT surged 51% YoY to ₹9 crores.
SteriPort capacity doubling to 12 crore bottles/year with commercialization slated for April 2026.
Total incremental revenue potential of ₹150 crores from SteriPort and SVP expansions.
10.8 MW captive solar plant to be commissioned by Q1 FY27, targeting ₹9 crores in annual cost savings.
EBITDA margins remained healthy at 21.3% for the 9-month period despite one-time IPO expenses.
💼 Action for Investors
Investors should monitor the successful ramp-up of the new SteriPort capacity in April 2026 as it is the primary driver for the projected ₹150 crore revenue growth. The stock remains attractive for long-term investors given the improving return ratios and structural cost advantages from the upcoming solar project.
Loading analysis...
Amanta Healthcare Q3 PAT Up 8% YoY; 9MFY26 PAT Surges 51% to ₹9.3 Cr
Amanta Healthcare reported a steady performance for Q3FY26 with revenue growing 9.84% YoY to ₹74.49 crore. The nine-month (9MFY26) performance was particularly strong in terms of profitability, with PAT surging 51.28% YoY to ₹9.3 crore. EBITDA margins for the 9-month period improved by 42 bps to 21.31%, although quarterly margins saw a slight compression of 159 bps. The company is currently executing a capacity expansion for high-margin SteriPort and SVP products, which is expected to drive growth from Q4 onwards.
Key Highlights
9MFY26 PAT increased by 51.28% YoY to ₹9.3 crore, driven by operational efficiency.
Q3FY26 Revenue grew 9.84% YoY to ₹74.49 crore, reflecting volume-led demand.
9MFY26 EBITDA margins expanded by 42 bps to 21.31% despite quarterly fluctuations.
The company is scaling high-margin SteriPort and SVP capacities to accelerate growth.
Green energy initiatives are being implemented for structural cost optimization.
💼 Action for Investors
Investors should monitor the commissioning of the new capacities in Q4, as management expects accelerated growth. The significant jump in 9-month profitability suggests improving operational leverage.
Loading analysis...
Amanta Healthcare Approves Q3 FY26 Unaudited Financial Results
Amanta Healthcare Limited's Board of Directors approved the standalone unaudited financial results for the quarter and nine months ended December 31, 2025. The statutory auditors, Price Waterhouse Chartered Accountants LLP, provided a Limited Review Report with an unmodified opinion, suggesting no material discrepancies in the reporting. The meeting was held on February 10, 2026, ensuring timely regulatory compliance with SEBI listing obligations. Investors should note that the audit opinion confirms the financial statements are prepared in accordance with Indian Accounting Standards.
Key Highlights
Board approved standalone unaudited financial results for the quarter and nine months ended December 31, 2025
Statutory auditor Price Waterhouse Chartered Accountants LLP issued a Limited Review Report with an unmodified opinion
The board meeting was conducted on February 10, 2026, between 12:00 PM and 01:00 PM
Compliance maintained under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015
💼 Action for Investors
Investors should review the detailed profit and loss statements to assess the company's margin performance and revenue growth. The clean auditor's report provides a level of assurance regarding the integrity of the financial disclosures.
Loading analysis...
Amanta Healthcare Corrects Solar Plant Capacity to 10.8 MWp for Captive Consumption
Amanta Healthcare Limited has clarified a significant clerical error regarding its solar power project, correcting the capacity from 10.8 KWp to 10.8 MWp. The company has re-executed its agreement with Zodiac Energy Limited to reflect this 1,000x increase in planned capacity. The 10.8 MWp plant will be located in Kheda, Gujarat, and is dedicated to captive consumption. This move is expected to substantially reduce the company's long-term energy costs and improve its ESG profile.
Key Highlights
Corrected solar power plant capacity from 10.8 KWp to 10.8 MWp
Agreement re-executed with Zodiac Energy Limited on January 02, 2026
Project located at Village Baroda, District Kheda, Gujarat
Plant intended for captive consumption to reduce operational electricity expenses
No other terms or conditions of the original agreement have been changed
💼 Action for Investors
Investors should view this correction positively as a 10.8 MWp plant represents a significant infrastructure investment compared to the previously stated minor installation. Monitor for future updates regarding the commissioning date and the resulting impact on operating margins.